INTRODUCTION
The GM2-activator is a lysosomal glycolipid-binding protein [1] and is an essential cofactor for in-viva degradation of ganglioside GM2 by ,-N-acetyl-D-hexosaminidase (EC 3.2.1.52; hexosaminidase A) [2] . Its genetic deficiency causes the abnormal accumulation of ganglioside GM2 in tissues of patients with the AB variant of GM2-gangliosidosis. The protein is synthesized as a pro-protein that is processed to the mature glycoprotein of approx. 22 kDa. The protein has been sequenced by Edman degradation and consists of 162 amino acids [3] . A cDNA has been isolated from a human-fibroblast library that encodes the mature GM2-activator [4] . Recently, the gene and two full-length cDNA clones of the GM2-activator were isolated and characterized [5] . A mutation in the GM2-activator gene has been identified in a patient with GM2-gangliosidosis variant AB [6] .
COS-1 cells transfected with an expression vector containing the GM2-activator protein cDNA generated a functional GM2-activator protein [7] .
For structural and functional studies, large amounts of active protein are needed. While some eukaryotic expression systems, for example, baby-hamster-kidney (BHK) cells or insect cells infected with an appropriate recombinant baculovirus, can produce sufficient amounts of recombinant proteins, a suitable purification procedure must be developed for the proteins generated. Large amounts can be generated in Escherichia coli as well by subcloning the cDNA together with a strong promotor into a prokaryotic expression vector that is designed to facilitate the subsequent purification ofthe recombinant protein generated.
An additional advantage is that E. coli has no endogenous GM2-activator, which facilitates purifying and characterizing normal and mutant GM2-activators. However, since the recombinant proteins produced by E. coli are not glycosylated, it is important to make sure that the GM2-activator generated by such a prokaryotic expression system is functional.
In this report we describe the expression of an appropriate protein that was purified from human tissue. When added to the culture medium, the recombinant carbohydrate-free GM2-activator, carrying the hexahistidine tail, could be taken up efficiently and restored the degradation of ganglioside GM2 to normal rates in mutant fibroblasts with the AB variant of GM2-gangliosidosis, which is characterized by a genetic defect in the GM2-activator protein. The prokaryotic expression system is useful for producing milligram quantities of a pure and functionally active GM2-activator.
cDNA construct in E. coli to yield a carbohydrate-free human GM2-activator fusion protein. This could be purified in a single step under denaturing conditions and could be renatured to yield a fully functional GM2-activator. The unprocessed GM2-activator was as active as the native activator isolated from human tissues in an in-vitro assay and could correct the metabolic defect of fibroblasts from a patient with GM2-gangliosidosis AB variant when added to the culture medium.
EXPERIMENTAL Materials
All chemicals were of the highest purity available commercially. Culture flasks (25 cm2, 75 cm2) were from Falcon (Becton Dickinson and Co., Paramus, NJ). Picofluor 30 was from Packard (Groningen, The Netherlands). Restriction endonucleases, T4 DNA ligase and the T7 sequencing kit were obtained from Pharmacia (Freiburg, Germany). The expression plasmid pQE-9, the E. coli host M15, transformed with the plasmid pREP4, and the Ni2+-nitrilotriacetic acid (NTA) agarose were purchased from Diagen (Hilden, Germany). Isopropyl /J-D-thiogalactopyranoside (IPTG), the yeast extract, bacto-tryptone, minimalessential medium (GIBCO no. 0410190 m) and Taq DNA polymerase were obtained from GIBCO-BRL (Eggenstein, Germany). The 'rainbow' protein standard was from Amersham (Braunschweig, Germany). The protease Factor Xa and glutathione were purchased from Boehringer (Mannheim, Germany). The preparation of reaction buffers and reaction conditions followed the recommendations of the suppliers in general.
Oligonucleotides were synthesized on a Pharmacia 'Gene Assembler Plus'. Ganglioside GMl was labelled in the sphingoid base using the method of Schwarzmann [8] .
Construction of the expression plasmid pHX17 ( Figure 1) A new BamHI restriction site and a cleavage site for the protease t To whom correspondence should be addressed.
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Figure 1 Construction and description of the expression vector pHX17
The vector was obtained from the plasmid pQE-9 by introducing a PCR-amplified cDNA construct containing the sequence for a Factor Xa-cleavage site and the mature GM2-activator (see also Figure 2a ). The plasmid pQE-9 belongs to the pDS-family [24] of plasmids and contains the regulatable promotor/operator element N250PSN250P29, which is repressed by the E. coli lac repressor but can be induced by IPTG, and the synthetic ribosomal-binding site (RBSII). It carries the gene for ampicillin resistance. The transcriptional terminator is from phage lambda.
Factor Xa (-Ile-Glu-Gly-Arg-Xaa-) were added on the 5' side of the coding region of the mature GM2-activator protein and a HindIll restriction site, re-creating the stop codon in the expression vector pQE-9 [9] , was created at the 3' end, by amplifying the GM2-activator cDNA by PCR with suitable synthetic-oligonucleotide primers (Figure 2a ). PCR amplification was performed using a Biometra thermocycler (Biometra, Gottingen, Germany). The amplified DNA was purified and digested with appropriate amounts of restriction enzymes. The host E. coli, Ml 5/pREP4 [10] , carrying the genes for kanamycin resistance and for the lac repressor on the plasmid pREP4 was made competent by treatment with CaCl2. They were transformed with the ligation products ( Figure 1 ) and were grown overnight on Luria broth (LB) plates containing ampicillin (100 ,g/ml) and kanamycin (50 ,ug/ml) at 37°C [11] . The recombinant plasmid pHX17 was isolated and characterized by Southern blotting and DNA sequencing.
When induced by IPTG, this plasmid generates the mature human GM2-activator protein fused to four amino acids encoded by the vector, six histidine residues followed by the Factor Xacleavage sequence on the amino terminus (Figure 2b ).
Isolation and characterization of the plasmid DNA Plasmid DNA was prepared using the method of Birnboim and Doly [12] . The plasmid DNA was purified further by chromatography on a column (Qiagen-tip 20, Diagen, Hilden, Germany) for sequencing. The insert was sequenced by the dideoxy chaintermination method [13] The cells were harvested by centrifugation (4000 g, 4°C, 15 min).The yield from 50 ml of the culture medium was 1.3 g of E. coli. Subsequent purification steps were carried out at room temperature. The cell pellet from a 50 ml culture was resuspended in 5 ml of extraction buffer (3 % v/v /-mercaptoethanol, 6 M guanidine hydrochloride and 0.1 M NaH2PO4, pH 8.0) for I h. After the extraction the cells were harvested by centrifuging (6000 g, room temperature, 15 min). The crude supernatant was loaded onto a column containing 3 ml of Ni2+-NTA agarose equilibrated with 11 ml of the extraction buffer. The recombinant GM2-activator protein was purified by immobilized metal-affinity chromatography [14] . On an Ni2+-NTA adsorbent (Quiagen, Hilden, Germany) the metal ions are co-ordinated by six ligands.
The hexahistidine residues of the recombinant GM2-activator bind with high affinity to the Ni2+ ions to form a stable complex.
The column was developed under mild conditions with a pHstep gradient (pH 8.0 loading step, pH 7.0 wash step and pH 5.0 elution of the product). The column was washed and was eluted sequentially with three column volumes of the extraction buffer, two volumes of the washing buffer (extraction buffer at pH 7.0) and two volumes of the elution buffer (extraction buffer at pH 5.0). All the fractions were collected in 2-ml samples. A sample of 100,1 from each fraction was dialysed against H20,
analysed by SDS/PAGE and stained with Coomassie Blue [15] .
Refolding of the recombinant GM2-activator Other analytical methods
The protein content was determined using the method of Bradford [17] with BSA as a standard. SDS/PAGE was done according to the method of Laemmli [18] .
Fibroblast culture and feeding studies Human-fibroblast cell lines were grown in monolayers to confluence and were handled as described previously [19] . At after reaching confluency, the fibroblasts were washed three times with culture medium containing 0.3 % (v/v) heat-inactivated fetal-calf serum. Then 25 cm2 culture flasks were incubated with 3 ml of medium containing 3 mnol [3H]G.1 per ml, labelled in the sphingoid base (specific activity, 4000 Ci molV1) and 0.3 % (v/v) heat-inactivated (30 min at 56°C) fetal-calf serum under cell-culture conditions for 70 h. After incubation the cells were washed three times with 1 ml of PBS (140 mM NaCl, 3 mM KCI, 16 mM Na2HPO4 and 1.5 mM KH2PO4), detached by incubating with 2.5 ml of 0.25 % trypsin in PBS for 15 min at 37°C and were isolated by centrifugation (1000 g, 4°C, 10 min). The cell pellet was washed three times with 1 ml of PBS. This procedure removed all adsorbed glycolipids from the cell surface effectively but did not remove the inserted or intracellular glycolipids [20] .
Incorporation of the GM2-activator Into fibroblast cells The recombinant GM2-activator or the human GM2-activator, purified from tissues, was added to the [3H]ganglioside GM1-containing medium (30 ,tg of human or of recombinant GM2-activator per 3 ml). Cells from patients with GM2-gangliosidosis variant AB (genetic GM2-activator deficiency) and variant B (genetic ,J-hexosaminidase a-subunit deficiency) were maintained in the glycolipid-and the GM2-activator-containing medium for 70 h under cell-culture conditions and then were harvested. The lipids were extracted from the cells as described below and were separated by t.l.c.
Extraction and t.I.c. of lipids
The cell pellets obtained from 25 cm2 culture flasks were resuspended in 5 ml of chloroform/methanol/water (60:30:6, by vol.) and were extracted for 48 h at 50 'C. Aliquots of the cell extracts were mixed with Picofluor (20 ml) and the total cellular radioactivity was determined by scintillation counting. Insoluble material was removed by centrifugation (6000 g, 4 'C, 20 min). The supernatant was adjusted to pH 11 by adding NaOH (4 M). The solution was incubated for 16 h at 40 'C. After neutralization with acetic acid, the lipid extract was dried under N2, resuspended in methanol/water/chloroform (47:48:3, by vol.) and loaded on RP-18 columns. The lipids were eluted from the columns with methanol followed by choloroform/methanol (1:1, by vol.). The fractions were pooled, applied to t.l.c. plates (Silica Gel 60, E. Merk, Darmstadt, Germany) and chromatographed with chloroform/methanol/0.22 % aqueous CaCl2 (65:35:8, by vol.).
Radioactive spots were visualized by fluorography [19] .
RESULTS
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A cDNA encoding the human GM2-activator, with a hexahistidine 156 tail and a Factor Xa cleavage site at its amino terminus, was 169 cloned into the expression vector pHX17 and was expressed in E. coli M 15. When induced by IPTG, production ofthe recombinant 178 GM2-activator could be observed already after 45 min and the maximum level was reached after 5 h. The product could be purified to near homogeneity by a single-step Ni2+-NTA affinity -acid column (Figure 3 ). The yield of the recombinant GM2-activator protein was approx. 1.4 mg per 50 ml of the culture medium. However, the purified GM2-activator was denatured due to the The recombinant GM2-activator containing the hexahistidine and the Factor Xa cleavage sequence at its amino terminus was purified under denaturating conditions and refolded. The protein was assayed in an in-vitro assay. The value given for the specific activity of the recombinant GM2-activator is the mean of 19 independent measurements on different preparations of the recombinant GM2-activator after refolding. An activator unit (AU) is defined by the amount of labelled GM2 ganglioside cleaved under standard conditions; 1 AU = 1 nmol [3H]GM2I(unit f-hexosaminidase A per min) [25] . The native GM2-activator refers to GM2-activator purified from post-mortem tissues of Gaucher patients [25] .
Specific activity GM2-activator (AU * mg-') Native Recombinant 70.5 96.0+ 16.0 procedure used was based on the method of Martson [21] . The protein was refolded by the step-wise dilution of guanidine hydrochloride and the slow oxidation of the cysteine groups to disulphide bonds by a glutathione-redox system. When assayed in the in-vitro system, the refolded recombinant GM2-activator, with the six histidine residues and the Factor Xa cleavage sequence still attached to the N-terminus of the protein, was at least as active as the native GM2-activator, purified from postmortem tissues of Gaucher patients ( Table 1 ). The hexahistidine residue could be removed by cleaving with Factor Xa and separating on an Ni2+-NTA column. The GM2-activator without the histidine residues passed through the column, while that with the hexahistidine still attached was adsorbed by the column. The yield was approx. 30%. The GM2-activator generated by this means had about the same specific activity as that with the hexahistidine tail. Therefore apparently the presence of the hexahistidine and of the Factor Xa-cleavage sequence did not affect the function of the GM2-activator. The recombinant GM2-activator was detected in a Western blot (data not shown) using polyclonal antibodies that had been raised against purified GM2-activator protein from human tissue, as described previously [22] . Cultured fibroblasts from patients with the AB variant of GM2-gangliosidosis are deficient genetically in the GM2-activator protein [1] and do not degrade exogenously added ganglioside GM2. It has been demonstrated previously that the capacity to degrade GM2 could be restored by adding purified GM2-activator to the culture medium [19] .
In our experiments, control fibroblasts could degrade [3H]-ganglioside GM1, labelled in the sphingoid moiety, added to the culture medium in a step-wise manner. The degradation was blocked, as expected, at the level of GM2 in fibroblasts from patients with GM2-gangliosidosis AB variant (Figure 4) .
Adding either the recombinant carbohydrate-free GM2-activator, with the hexahistidine tail still attached, or the native glycosylated GM2-activator, purified from the post-mortem tissues of a Gaucher patient, to the culture medium of AB-variant cells eliminated the block on GM2-ganglioside degradation completely. Therefore the activator was extracted under strongly denaturing conditions in the presence of 6M guanidine hydrochloride and 3 % (v/v) fl-mercaptoethanol. The eight cysteine residues in the mature GM2-activator can form four disulphide bonds that may be essential for its activity. The renaturation procedure described was devised after much trial and error and, while the procedure effectively renatures the GM2-activator, different proteins are likely to require different renaturing conditions that must be defined empirically.
In the in-vitro assay [25] , the recombinant and renatured GM2-activator was consistently slightly more active than the native GM2-activator purified from post-mortem tissues of Gaucherdisease patients. We interpret this to mean that the native GM2-activator preparation, after many tedious purification steps, is still not as pure as the recombinant GM2-activator after the single-step purification, or that the native activator is inactivated partially during the long purification procedure. We determined that the very low concentrations of detergent (0.003 % v/v Tween 20) in the folding buffers did not affect the outcome of the in-vitro GM2-activator assay.
Similarly the recombinant carbohydrate-free GM2-activator was in every respect at least as effective as the purified native activator in restoring the GM2-catabolizing capacity of cultured fibroblasts from patients with GM2-gangliosidosis AB variant. This indicated that the GM2-activator without carbohydrate chains could be taken up by these cells as efficiently as the glycosylated native GM2-activator.
Initially we were apprehensive that the presence of foreign amino acids (four amino acids encoded by the vector, six histidines and four amino acids of the Factor Xa recognition sequence) and the lack of glycosylation might affect the function of the GM2-activator; however neither factor affected the activity. The activity was unchanged before and after the removal of the foreign amino acids, which can be removed with reasonable efficiency anyway, if the purpose and design of experiments make them undesirable. The high activity compared to the glycosylated native activator similarly confirmed that the carbohydrate chain is not essential for the GM2-activator activity.
The equal effectiveness of the native and of the recombinant GM2-activator in correcting the defective catabolism of the GM2-ganglioside in the GM2-gangliosidosis AB variant fibroblasts indicates that a mechanism that can take up the activator added to the culture medium exists that is independent of the carbohydrate chain. The carbohydrate-free GM2-activator is quite likely to be bound to glycolipids at the-cell surface and then taken up by endocytosis to the lysosome. However glycosylation is expected to be essential for the normal cellular function and for the routeing of the endogenously synthesized GM2-activa to the lysosomes. Another sphingolipid activator, sap-B, also retains its in-vitro activator function when deglycosylated, but a mutation that abolishes its glycosylation site is known to result in a sap-Bdeficiency phenotype that resembles metachromatic leukodystrophy [23] .
The prokaryotic over-expression system should be useful to isolate large amounts of functionally active GM2-activator that could be used for X-ray crystallography, n.m.r. spectroscopy and for detailed studies of the enzymic reaction mechanism of GM2-ganglioside hydrolysis.
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